Pantoprazole: profile and news

Teva gets FDA approval for pantoprazole sodium DR tablets  Apr 23, 2006
...tentative approval for the company's abbreviated new drug application (ANDA) to market its generic version of Wyeth's Protonix (pantoprazole sodium) delayed ... - Globes,

STABILITY OF OMEPRAZOLE SODIUM AND PANTOPRAZOLE SODIUM DILUTED FOR ...  Apr 21, 2006
Currently, the manufacturers of omeprazole and pantoprazole injections recommend that infusions prepared by dilution in NaCl 0.9% should be used within 12 or 3 ... - The Journal of Pharmacy Technology

Altana Q1 EBIT up 23 pct on booming sales of ulcer drug ...  Apr 27, 2006
AFX) - Altana AG said first quarter EBIT reached 185 mln eur, up 23 pct from 150 mln last year, thanks to increased sales of its Pantoprazole stomach ulcer ... - Forbes

ALTANA Delivers Excellent 1st Quarter 2006  Apr 27, 2006
The operating return (EBITDA) was 29%. Pantoprazole (Pantozol(R)/Protonix(R)), the innovative gastrointestinal drug, continues to deliver strong growth. ... - Genetic Engineering News,

Teva Receives Tentative Approval for Generic Protonix(R) Delayed ...  Apr 21, 2006
...tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Wyeth's Protonix(R) (Pantoprazole Sodium) Delayed ... - International News Service,

Bayer, Merck and Altana See Surge in First-Quarter Drug Profit  Apr 27, 2006
...to sell its pharmaceutical business, said its 25 percent earnings gain and the 28 percent increase in sales were helped by demand for ulcer drug Pantoprazole. ... - Bloomberg

AFX European summary - midday  Apr 27, 2006
AFX) - Altana AG said first-quarter EBIT reached 185 mln eur, up 23 pct from 150 mln last year, thanks to increased sales of its Pantoprazole stomach ulcer ... - Forbes

Teva's generic Protonix gets FDA approval  Apr 21, 2006
Teva's pantoprazole sodium DR (delayed release) tablets are the equivalent of Wyeth's Protonix DR tablets. The brand name had 2005 sales of about $2.4 billion. ... - BusinessWeek

WRAPUP 1-German drug-chemical hybrids post strong results  Apr 27, 2006
Altana beat forecasts with a 23 percent rise in quarterly operating earnings thanks to strong sales of flagship anti-ulcer drug pantoprazole and the ... - Reuters

ADR Report: Latin America, Asia Lift Composite Index -2-  Apr 21, 2006
...hypersecretory conditions. Israel's Teva is currently involved in a patent-litigation lawsuit over its pantoprazole sodium tablets. The ... - Yahoo! News

Altana First-Quarter Net Rises 25% After Eckart Takeover  Apr 26, 2006
Altana gets more than 40 percent of its sales from Pantoprazole, a stomach ulcer drug that competes with AstraZeneca Plc's Nexium. ... - Bloomberg

Teva Granted Tentative FDA Approval For Generic Protonix Delayed ...  Apr 21, 2006
...its Abbreviated New Drug Application to market its generic version of Wyeth's Protonix Delayed Release Tablets, 20 mg and 40 mg.Teva's Pantoprazole Sodium DR ... - Trading Markets,

Teva OK'd on generic of Wyeth's Protonix  Apr 21, 2006
Food and Drug Administration has given tentative approval to its generic version of Wyeth's Protonix Sodium Delayed Release Tablets (pantoprazole sodium) in 20 ... - United Press International

EARNINGS PREVIEW: Altana 1Q Net Profit Seen +19% On Year  Apr 25, 2006
Sales are forecast to rise 25% to EUR927.4M vs EUR741M. The earnings driver continues to be the drug for gastrointestinal treatment, pantoprazole. ... - newratings.com

Indigestion defined  Apr 29, 2006
...adenosine triphosphate enzyme system�. Examples are omeprazole, pantoprazole, esomeprazole and lansoprazole. H. pylori can be ... - Malaysia Star,

First Quarter Report 2006: Schwarz Pharma with a Good Start  Apr 25, 2006
Sales of the gastrointestinal drug Rifun® (pantoprazole) decreased by 10.3% to €10.6 million as a result of the wholesalers’ caution due to the upcoming ... - PharmaLive.com (press release),

Pantoprazole is metabolized through the cytochrome P450 system, primarily the CYP2C19 and CYP3A4 isozymes, and subsequently undergoes Phase II conjugation.

Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. Clinically relevant interactions of pantoprazole with other drugs with the same metabolic pathways are not expected. Therefore, when coadministered with pantoprazole, adjustment of the dosage of pantoprazole or of such drugs may not be necessary. There was also no interaction with concomitantly administered antacids. There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time.

Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).

Laboratory Tests

There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. An alternative confirmatory method should be considered to verify positive results.